195 related articles for article (PubMed ID: 20428925)
21. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
[TBL] [Abstract][Full Text] [Related]
22. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors.
Abramovich CM; Prayson RA
Hum Pathol; 1998 Dec; 29(12):1420-7. PubMed ID: 9865827
[TBL] [Abstract][Full Text] [Related]
23. Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes.
Durand A; Champier J; Jouvet A; Labrousse F; Honnorat J; Guyotat J; Fèvre-Montange M
Clin Neuropathol; 2008; 27(5):334-45. PubMed ID: 18808065
[TBL] [Abstract][Full Text] [Related]
24. WHO grade II and III meningiomas: a study of prognostic factors.
Durand A; Labrousse F; Jouvet A; Bauchet L; Kalamaridès M; Menei P; Deruty R; Moreau JJ; Fèvre-Montange M; Guyotat J
J Neurooncol; 2009 Dec; 95(3):367-375. PubMed ID: 19562258
[TBL] [Abstract][Full Text] [Related]
25. Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker.
Parada CA; Osbun JW; Busald T; Karasozen Y; Kaur S; Shi M; Barber J; Adidharma W; Cimino PJ; Pan C; Gonzalez-Cuyar LF; Rostomily R; Born DE; Zhang J; Ferreira M
Clin Cancer Res; 2020 Jan; 26(1):193-205. PubMed ID: 31615938
[TBL] [Abstract][Full Text] [Related]
26. Overexpression of STMN1 is associated with the prognosis of meningioma patients.
Wang H; Li W; Wang G; Zhang S; Bie L
Neurosci Lett; 2017 Jul; 654():1-5. PubMed ID: 28625575
[TBL] [Abstract][Full Text] [Related]
27. The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas.
Sughrue ME; Kane AJ; Shangari G; Rutkowski MJ; McDermott MW; Berger MS; Parsa AT
J Neurosurg; 2010 Nov; 113(5):1029-35. PubMed ID: 20380529
[TBL] [Abstract][Full Text] [Related]
28. Histopathologic features and MIB-1 labeling indices in recurrent and nonrecurrent meningiomas.
Abramovich CM; Prayson RA
Arch Pathol Lab Med; 1999 Sep; 123(9):793-800. PubMed ID: 10458826
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors for patients with World Health Organization grade III meningiomas treated at a single center.
Shan B; Zhang J; Song Y; Xu J
Medicine (Baltimore); 2017 Jun; 96(26):e7385. PubMed ID: 28658170
[TBL] [Abstract][Full Text] [Related]
30. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management.
Gousias K; Schramm J; Simon M
J Neurosurg; 2016 Sep; 125(3):551-60. PubMed ID: 26824369
[TBL] [Abstract][Full Text] [Related]
31. Surgery for convexity meningioma: Simpson Grade I resection as the goal: clinical article.
Hasseleid BF; Meling TR; Rønning P; Scheie D; Helseth E
J Neurosurg; 2012 Dec; 117(6):999-1006. PubMed ID: 23061394
[TBL] [Abstract][Full Text] [Related]
32. p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.
Barresi V; Branca G; Caffo M; Tuccari G
J Neurooncol; 2015 Mar; 122(1):87-95. PubMed ID: 25563814
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
34. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
[TBL] [Abstract][Full Text] [Related]
35. Decrease in serine protease HtrA1 expression correlates with grade and recurrence in meningiomas.
Önder E; Arıkök AT; Seçkin H; Alper M
Adv Med Sci; 2015 Mar; 60(1):139-43. PubMed ID: 25687108
[TBL] [Abstract][Full Text] [Related]
36. Significance of the Extent of Resection in Modern Neurosurgical Practice of World Health Organization Grade I Meningiomas.
Winther TL; Torp SH
World Neurosurg; 2017 Mar; 99():104-110. PubMed ID: 27867123
[TBL] [Abstract][Full Text] [Related]
37. Differential Tumor Progression Patterns in Skull Base Versus Non-Skull Base Meningiomas: A Critical Analysis from a Long-Term Follow-Up Study and Review of Literature.
Savardekar AR; Patra DP; Bir S; Thakur JD; Mohammed N; Bollam P; Georgescu MM; Nanda A
World Neurosurg; 2018 Apr; 112():e74-e83. PubMed ID: 29258946
[TBL] [Abstract][Full Text] [Related]
38. Karyopherin a2 and chromosome region maintenance protein 1 expression in meningiomas: novel biomarkers for recurrence and malignant progression.
Gousias K; Niehusmann P; Gielen GH; Simon M
J Neurooncol; 2014 Jun; 118(2):289-296. PubMed ID: 24664371
[TBL] [Abstract][Full Text] [Related]
39. Clinical and histopathological analysis of proliferative potentials of recurrent and non-recurrent meningiomas.
Matsuno A; Fujimaki T; Sasaki T; Nagashima T; Ide T; Asai A; Matsuura R; Utsunomiya H; Kirino T
Acta Neuropathol; 1996; 91(5):504-10. PubMed ID: 8740231
[TBL] [Abstract][Full Text] [Related]
40. Proteins involved in regulating bone invasion in skull base meningiomas.
Salehi F; Jalali S; Alkins R; Lee JI; Lwu S; Burrell K; Gentili F; Croul S; Zadeh G
Acta Neurochir (Wien); 2013 Mar; 155(3):421-7. PubMed ID: 23238945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
